— Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a loss of $67.2 million or $1.21 per share last year.
— Total revenues edged up to $6.01 million from $5.9 million in 2018
— Research and development expenses were almost unchanged year-over-year at $57.6 million in fiscal 2019
— Achieved progress in a focused discovery effort on follow-on compounds for the current HBV pipeline
— On track to advance a next-generation oral HBV specific RNA-destabilizer with chemical scaffolds distinct from AB-452 through lead optimization
— Ended 2019 with $90.8 million in cash, cash equivalents and short-term investments
— Expects to utilize between $54 to $58 million of cash and investments to fund operations in 2020
Business consulting services provider Accenture (NYSE: ACN) reported its fourth quarter and fiscal 2020 earnings last Thursday. Accenture's failure to meet the market's earnings and revenue targets and the weak
Stock markets shifted to recovery mode as the week came to a close, with the major indices closing higher after staying in the negative territory in the past few weeks.
Renewable energy companies have been gaining attraction in the market due to the strong potential they have. Many countries are now relying mainly on renewable energy for their power consumption.